1. Home
  2. SEED vs NOTV Comparison

SEED vs NOTV Comparison

Compare SEED & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Agritech Limited

SEED

Origin Agritech Limited

HOLD

Current Price

$1.30

Market Cap

12.6M

ML Signal

HOLD

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.28

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEED
NOTV
Founded
1997
1974
Country
China
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6M
10.8M
IPO Year
2005
1997

Fundamental Metrics

Financial Performance
Metric
SEED
NOTV
Price
$1.30
$0.28
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
121.9K
427.5K
Earning Date
01-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
49.64
EPS
N/A
N/A
Revenue
N/A
$547,656,000.00
Revenue This Year
N/A
$5.28
Revenue Next Year
N/A
$5.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
511.19
52 Week Low
$0.82
$0.25
52 Week High
$2.49
$3.31

Technical Indicators

Market Signals
Indicator
SEED
NOTV
Relative Strength Index (RSI) 51.51 39.03
Support Level $0.96 $0.26
Resistance Level $1.37 $0.46
Average True Range (ATR) 0.15 0.05
MACD 0.00 -0.00
Stochastic Oscillator 34.00 0.71

Price Performance

Historical Comparison
SEED
NOTV

About SEED Origin Agritech Limited

Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: